Precigen (PGEN) Competitors

Precigen has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.91, indicating that its share price is 91% more volatile than the broader market.

Rhythm Pharmaceuticals has higher revenue and earnings than Precigen. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

In the previous week, Precigen had 8 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 9 mentions for Precigen and 1 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.60 beat Precigen's score of -0.08 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

33.5% of Precigen shares are owned by institutional investors. 47.1% of Precigen shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Rhythm Pharmaceuticals' return on equity.

Precigen presently has a consensus target price of $12.50, suggesting a potential upside of 249.16%. Rhythm Pharmaceuticals has a consensus target price of $131.81, suggesting a potential upside of 52.56%. Given Precigen's higher possible upside, equities analysts clearly believe Precigen is more favorable than Rhythm Pharmaceuticals.

Cogent Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Precigen has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

Cogent Biosciences has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Cogent Biosciences' return on equity.

Precigen has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

33.5% of Precigen shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by company insiders. Comparatively, 47.1% of Precigen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cogent Biosciences presently has a consensus target price of $43.73, indicating a potential upside of 40.96%. Precigen has a consensus target price of $12.50, indicating a potential upside of 249.16%. Given Precigen's higher probable upside, analysts plainly believe Precigen is more favorable than Cogent Biosciences.

In the previous week, Precigen had 8 more articles in the media than Cogent Biosciences. MarketBeat recorded 9 mentions for Precigen and 1 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.40 beat Precigen's score of -0.08 indicating that Cogent Biosciences is being referred to more favorably in the media.

Precigen has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Precigen presently has a consensus price target of $12.50, suggesting a potential upside of 249.16%. Centessa Pharmaceuticals has a consensus price target of $41.33, suggesting a potential upside of 4.32%. Given Precigen's stronger consensus rating and higher possible upside, research analysts plainly believe Precigen is more favorable than Centessa Pharmaceuticals.

Centessa Pharmaceuticals has lower revenue, but higher earnings than Precigen. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

In the previous week, Precigen had 7 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 9 mentions for Precigen and 2 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.77 beat Precigen's score of -0.08 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Centessa Pharmaceuticals has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Centessa Pharmaceuticals' return on equity.

33.5% of Precigen shares are owned by institutional investors. Comparatively, 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 47.1% of Precigen shares are owned by company insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Precigen presently has a consensus price target of $12.50, suggesting a potential upside of 249.16%. Scholar Rock has a consensus price target of $56.00, suggesting a potential upside of 26.41%. Given Precigen's higher probable upside, research analysts clearly believe Precigen is more favorable than Scholar Rock.

Scholar Rock has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Scholar Rock's return on equity.

Precigen has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Precigen has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

In the previous week, Precigen had 6 more articles in the media than Scholar Rock. MarketBeat recorded 9 mentions for Precigen and 3 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.00 beat Precigen's score of -0.08 indicating that Scholar Rock is being referred to more favorably in the news media.

33.5% of Precigen shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 47.1% of Precigen shares are held by company insiders. Comparatively, 13.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.